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Characterization of three novel monoclonal 
anti-Oka
M.H. Tian and G.R. Halverson
Anti-Oka was first described by Morel and Hamilton in 1979. The Oka 
antigen has a very high incidence, and only eight probands that are 
Ok(a–) have been found; all are of Japanese heritage. In this study, 
we describe the generation and characterization of three novel mono-
clonal antibodies (Mabs), MIMA-25, MIMA-144, and MIMA-149. The 
reactivity of these three Mabs was compared with the original human 
polyclonal anti-Oka. Mice were immunized with transfected HEK cells 
to induce an immune response, and the spleen B lymphocytes were 
fused with mouse myeloma X63-Ag8.653 cells to form antibody-
secreting hybridomas. The resulting Mabs were tested serologically, by 
flow cytometry, and by immunoblotting. The specificity of each anti-
body was determined after excluding specificities to common antigens 
in the Rh, Kell, Duffy, Kidd, MNS, Lewis, Lutheran, P1, Colton, Diego, 
Xga, and Dombrock blood group systems. In each case only the Ok(a–) 
RBC sample was nonreactive. The Mabs and the original human anti-
Oka each have a unique pattern of reactivity when tested with enzyme-
treated cells; however, none were reactive by immunoblotting. We 
have generated three novel anti-Oka Mabs: MIMA-144 is an indirectly 
agglutinating IgG2b antibody, and MIMA-25 and MIMA-149 are di-
rectly agglutinating antibodies (IgM and IgA, respectively), underscor-
ing their usefulness as typing reagents for the clinical laboratory. 
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Commercial reagents for antigen typing RBCs have commonly been derived from polyclonal human serum collected from hyperimmunized donors. 
However, the direct immunization of human subjects is no 
longer recommended by the FDA, thus the supply of human 
polyclonal reagents is rapidly diminishing and becoming in-
creasingly more expensive to maintain. Kohler and Milstein 
first reported the successful development of a monoclonal 
antibody–producing hybridoma cell line.1 Monoclonal anti-
bodies (Mabs) are now commonly used as blood typing re-
agents, replacing the need for human polyclonal reagents.2
 Although producing antibodies to carbohydrate anti-
gens (ABO, Lewis) was relatively easy, developing Mabs to 
other types of antigens has proven to be much more diffi-
cult.3–5 Furthermore, the early methods applied only to the 
murine model. The production of Mabs for human antigens 
requires a highly immunized donor, the viral transforma-
tion of human B lymphocytes, and a successful fusion with 
a mouse myeloma cell line.6 Transformation was needed 
to expand the number of human B lymphocytes for fusion, 
and, fortunately, it was found to improve the susceptibility 
of B lymphocytes for somatic cell hybridization by up to 25-
fold.7-8 Unfortunately, heterohybridoma cell lines have been 
found to be highly unstable, and thus more likely to stop 
secreting antibody after 6 to 12 months.9-10 As our work in 
the production of Mabs to blood group antigens developed, 
so too did the use of novel approaches to achieve an immune 
response in the mouse that would lead to the development 
of murine-based Mabs to human blood group antigens.11–13
The OK Blood Group System    
 The antibody Oka was named for the family name of the 
proband (S.Ko.G) whose plasma reacted with all normal 
RBCs.14 Born of consanguineous parents on a small island 
off the coast of Onomichi, Honshu, Japan, the proband also 
had two siblings who were Ok(a–). Anti-Oka reacted by the 
antiglobulin test with blood samples from more than 4000 
Japanese donors. Since its discovery there have been only 
eight Ok(a–) probands identified, all in persons of Japanese 
heritage.15 Of more than 12,000 blood donors of various 
ethnic backgrounds tested in the United States, no other 
Ok(a–) individuals have been found.
 The Oka antigen is the only antigen in the OK blood 
group system and was assigned the ISBT # 024001 after 
it was located on CD147 glycoprotein and thereby was eli-
gible for blood group system status. The OK glycoprotein 
is a single-pass type I membrane glycoprotein with two Ig 
superfamily (IgSF) domains and a short transmembrane 
and cytoplasmic domain. Sequence analysis showed the N-
terminal 30 amino acids are identical to the predicted se-
quence of the M6 leukocyte activation antigen, which is a 
member of the IgSF. The OK gene consists of seven exons 
distributed over 1.8 kbp of gDNA, and it was localized using 
somatic cell genetics to chromosome 19, subregion 19p13.2-
pter.16 The rare Ok(a–) phenotype is the result of an amino 
acid substitution in the Ok glycoprotein (Ok(a+) > Ok(a–); 
E92K) encoded by exon 4 of OK.17
 The Ok glycoprotein (CD147) is the most common pro-
tein found in the membranes of leukocytes having a role 
in cell-cell interaction and in signal transduction, and it 
is thought to act as a tumor growth factor stimulating the 
production of collegenase and other cell invasion inducers. 
This glycoprotein is almost ubiquitous in that it is found 
on blood cells (RBCs, WBCs, and platelets) and in tissues 
of the renal cortex, liver, pancreas, colon, cervix, testes, 
smooth muscle, and brain.
 The first monoclonal anti-Oka was produced by Andrews 
et al. in 1983.18 in this paper we will describe the production 
and characterization of three new murine antibodies to the 
high-incidence Oka antigen. They were evaluated serologically 
for specificity, titer and score, immunoglobulin isotype, and 
reactivity pattern when tested with enzyme-treated RBCs. 
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They were also tested by flow cytometry and by immuno- 
blotting.
Materials and Methods    
Immunization Protocol    
 Two mice were immunized biweekly for 6 weeks with 
2 million human embryonic kidney (HEK) cells that had 
been transfected with human cDNA along with a CpG 
adjuvant specific for murine Mab production.18 After the 
immune response was verified by serum hemagglutina-
tion, the spleen was removed and splenocytes obtained by 
pulverizing the spleen with sterile glass slides.
Cellular Fusions  
 Fusions between the splenocytes and the mouse my-
eloma cell line (X63-Ag8.653) were done using polyethyl-
ene glycol (PEG, mol. wt., 3450) in a ratio of 3:1 spleen 
to myeloma cells, respectively. Fusions were performed by 
drop-wise addition of 1.0 mL of PEG to the washed, dry 
cells in a conical centrifuge tube with constant mixing for 
60 seconds. This was followed immediately by submerging 
the centrifuge tube into a 37°C water bath for 90 seconds 
with constant mixing, after which a drop-wise addition of 
1 mL of sterile phosphate buffered saline (PBS, pH 7.3, 
Gibco, Grand Island, NY) without calcium and magne-
sium was added for 60 seconds. This step was repeated, 
and then followed by the addition of 2 mL of PBS for 120 
seconds. This was continued until the total volume was 
approximately 15 mL. The now fused sample was rested 
for 15 minutes in the 37°C CO
2
 incubator, and then gently 
centrifuged.  The PBS was removed and the cells were sus-
pended in culture media (HAMS/DF-12; Sigma Chemicals, 
St. Louis, MO) that had been supplemented with 10 per-
cent fetal calf serum and hypoxanthine-adenine-thymidine 
(HAT) media (Sigma). The fused cells were gently mixed, 
then spread over 96-well flat-bottom culture trays at 100 
μL per well. After 1 week, fresh culture media supplemented 
with hypoxanthine-thymidine and gentamicin, but without 
aminopterin (StemCell Technologies, Vancouver, BC), was 
added as a selection media. After another week, the result-
ing hybrids were screened by hemagglutination in v-well 
microtiter trays for antibody production.
Hemagglutination Assays of 96-Well V-Well Trays  
 The supernatant culture fluid was assayed for reactiv-
ity with selected RBCs by 96-well v-bottom microtiter trays 
(Greiner Labs, Germany, www.GBO.com). For v-well as-
says, 50 μL of supernatant fluid (SNF) was removed from 
each well of the fusion trays and placed in the correspond-
ing well on the v-well assay tray. To this, 25 μL of a 1% 
suspension of human Ok(a+) RBCs in PBS was added, 
followed by mixing on a mechanical plate mixer (Labline 
Instruments Inc., Melrose Park, IL). The reactions were al-
lowed to settle for 30 minutes and then observed for direct 
agglutination. The cells were washed in PBS, and 50 μL of 
anti-mouse IgG diluted 1:100 in 6 percent BSA and PBS 
was then added to each well. The trays were again mixed, 
allowed to settle, and observed for indirect agglutination.
Hemagglutination in Tube and Gel Cards
 Standard hemagglutination assays were done in test 
tubes using one drop of a 3 percent RBC suspension in PBS 
plus two drops of Mab. MIMA-25 was incubated at room 
temperature for 30 minutes with Lo-Ion (Immucor/Gam-
ma, Norcross, GA) added to enhance reactions, then spun 
and read. MIMA-149 was incubated at room temperature 
for 30 minutes, spun, and read. MIMA-144 was incubated 
for 30 minutes at room temperature and tested by IAT us-
ing anti-mouse IgG (The Binding Site, San Diego, CA) that 
had been diluted 1:50 in 6% bovine serum albumin (BSA) in 
PBS.
 For the IgG gel card (DiaMed ID-PNH, Cressier, Swit-
zerland), 50 μL of a 1 percent suspension of Oka(+) RBCs 
and 25 μL of the Mab were added to each column, incu-
bated at 37°C for 15 minutes, and then centrifuged and read 
for agglutination.
Cloning by Limiting Dilution
 When a colony of hybrid cells is found to be producing 
the antibody of interest, the hybrids are counted and dilut-
ed such that there will be a finite number of cells in a 20-mL 
dilution. This dilution is done so that there will statistically 
be a limited number of cells per well when they are pipetted 
into 96-well flat-bottom cloning trays. Three clonings were 
done to ensure that the final product is from a monoclonal 
cell line. The initial cloning was done at 10, 5, and 2 cells per 
well to promote the development of a stable hybridoma cell 
line. The next two clonings were done at a dilution of 5, 2, 
and 1 cell per well. The final antibody was selected from the 
last set of cloning trays.
Enzyme Treatment of RBCs
 Human RBCs that had been pretreated with a variety of 
enzymes or reducing chemicals were tested by standard he-
magglutination methods to determine whether the Oka an-
tigen detected by the antibodies was resistant or sensitive to 
the enzyme effect on the protein.19 This included treatment 
with papain, trypsin, α
1
-chymotrypsin, pronase, neuramini-
dase, and 0.2 M dithiothrietol (DTT). The original human 
anti-Oka was tested in parallel.
Flow Cytometric Analysis
 A 1% RBC suspension of test RBCs was first incubated 
with 500 μL of each Mab and incubated at 37°C for 30 min-
utes, and then washed with PBS. The antibody-sensitized 
RBCs were then stained with fluoresceinisothiocyanate 
(FITC)-tagged anti-mouse antiglobulin (IgG from Vector 
Labs, Burlingame, CA; IgA and IgM from Southern Bio-
technology Associates, Birmingham, AL) by incubating in 
the dark at 4°C for a minimum of 15 minutes with frequent 
mixing to ensure adequate staining. The analytes were 
brought up to a final volume of 250 μL with PBS. Data were 
Serologic and flow cytometry evaluation of monoclonal anti-Oka
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acquired on a FACSCaliber flow cytometer (BD Biosciences, 
San Jose, CA) and analyzed with Cell Quest Pro software 
(BD Biosciences).
Results
 MIMA-25, MIMA-144, and MIMA-149 are specific for 
the Oka antigen (Fig. 1).21 MIMA-144 is an indirectly agglu-
tinating Mab, while MIMA-25 and MIMA-149 are directly 
agglutinating Mabs. Their isotype, titer, score, and reactions 
with enzyme and chemically pretreated Ok(a+) RBCs are 
shown in Table 1. When tested in parallel with the original 
human anti-Oka , they were found to have different reactivi-
ty patterns when tested with enzyme or chemically modified 
RBCs. MIMA-25 was strongly reactive with Ok(a+) RBCs 
that were treated with trypsin, pronase, and neuraminidase, 
and weaker with papain, α
1
-chymotrypsin, and 0.2 M DTT. 
MIMA-144 was weakly reactivity with Ok(a+) cells treated 
with papain, trypsin, and α
1
-chymotrypsin.  It was sensitive 
to treatment with pronase and neuraminidase, but resistant 
to treatment with 0.2M DTT. MIMA-149 was resistant to 
treatment with trypsin and pronase and weakly reactive 
with treatments of papain, α
1
-chymotrypsin, neuramini-
dase, and 0.2M DTT. The reactivity of the polyclonal anti-
Oka with Ok(a+) RBCs was unaffected by treatment with 
trypsin, α
1
-chymotrypsin, pronase, and 0.2M DTT, weak-
ened when treated with papain, and sensitive to treatment 
with neuraminidase.
 By flow cytometry each antibody demonstrated a posi-
tive change in fluorescence when compared with the negative 
control (Fig. 2). MIMA-149 demonstrated the best inten-
sity and specificity, with a sharp, narrow peak suggesting 
that its epitope is a short sequence of amino acids. MIMA-
144 showed a broader pattern of reactivity indicative of 
an epitope of a wider amino acid sequence. MIMA-25 was 
much weaker, with only a slight right shift, probably due to 
the isotype and low titer of this antibody. Flow cytometry of 
the native HEK cells shows the presence of the Oka antigen 
on untransfected cells, and the expression seems to be stron-
ger than the expression on normal human RBCs (Fig. 3).
 None of the Mabs were reactive by immunoblotting (re-
sults not shown).
Discussion
 We had previously reported that the HEK cells, wheth-
er transfected with human cDNA or not, had a high enough 
expression of CD147 to initiate an immune response, and 
this is the reason why we were able to produce so many dif-
ferent Mabs to Oka. MIMA-25, -144, and -149 are new anti-
Oka Mabs as demonstrated by their specific reaction with 
Table 1. Isotype, titer (score), and effect of enzymes and chemicals on Ok(a+) RBCs
Antibody Isotype
Titer 
(score) Papain Trypsin α1-Chymotrypsin Pronase Neuraminidase
0.2 M 
Dithiothreitol
MIMA-25 IgM 8 (29) Weak Resistant Weak Resistant Resistant Weak
MIMA-144 IgG2b 128 (77) Weak Weak Weak Sensitive Sensitive Resistant
MIMA-149 IgA 32 (55) Weak Resistant Weak Resistant Weak Weak
Human anti-
Oka
Not tested Not tested Weak Resistant Resistant Resistant Sensitive Resistant
MIMA-25 MIMA-144 MIMA-149
Ok(a+) Ok(a–) Ok(a+) Ok(a–) Ok(a+) Ok(a–)
Fig. 1  Gel card photo of Mab reactivity with Ok(a+) and Ok(a–) 
RBCs.
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Serologic and flow cytometry evaluation of monoclonal anti-Oka
Ok(a+) RBCs, and their nonreactivity with six different 
Ok(a–) RBC samples (M. Uchikawa, personal communica-
tion). The reactivity pattern of each antibody is unique in 
the way it is affected when RBCs are modified by 0.2M DTT 
or various enzymes. All three antibodies react well in test 
tubes and gel cards. With our flow cytometry data, it is not 
surprising that MIMA-25 was much weaker, as it is an IgM 
Mab requiring very careful dilution controls for demonstra-
tion of the reactivity by flow cytometry. Serologically this 
antibody works best by hemagglutination in the presence of 
Lo-Ion to enhance the reactions.
 None of these Mabs were reactive by Western blotting, 
suggesting that the epitope(s) they recognize may be con-
formation dependent.
Conclusions
 The three Mabs are unique antibodies that will be use-
ful for testing patients and screening blood donors to find 
Ok(a–) blood. MIMA-144 is an indirect agglutinating anti-
body, and MIMA-25 and MIMA-149 are directly agglutinat-
ing antibodies, and as such, are ideal reagents for rapidly 
typing RBCs.
Acknowledgments
 We thank Robert Ratner for the preparation of the 
manuscript, tables, and figures. We thank Wu He for his as-
sistance in performing the flow cytometry experiments, and 
Makoto Uchikawa for additional testing with Ok(a) RBC 
samples. We thank Karina Yazdanbakhsh for her review of 
and comments on the manuscript. This work was funded in 
part by a grant from the MetLife Foundation.
Oka is Expressed at High 
Levels on 293T Cells Ok
a Expression on RBCs
Fig. 3  Flow cytometry of transfected 293T cells and human Ok(a+) RBCs.
Fig. 2  Flow cytometry results with three Mabs against 
Ok(a+) and Ok(a–) RBCs.  On the x-axis is the fluorescent 
intensity of the signal and on the y-axis is the number of cells 
counted.  The shaded gray area represents the FITC-positive 
cell population.  The unshaded graph represents the negative 
control cell population.
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